Detalhe da pesquisa
1.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Mol Cancer
; 23(1): 61, 2024 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519913
2.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Acta Oncol
; 63: 385-391, 2024 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38779910
3.
Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.
Support Care Cancer
; 32(6): 353, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748187
4.
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Lancet Oncol
; 19(9): 1180-1191, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30120041
5.
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Eur J Cancer
; 202: 114000, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493667
6.
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.
Crit Rev Oncol Hematol
; 181: 103888, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460264
7.
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.
Cancer Discov
; 13(5): 1116-1143, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862804
8.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Cell Rep Med
; 4(12): 101307, 2023 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38056464
9.
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Eur J Cancer
; 167: 42-53, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378410
10.
Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers.
Cancer Treat Res Commun
; 32: 100611, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905672
11.
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.
Eur J Cancer
; 173: 133-145, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35872509
12.
PALLIA 10 score in phase I cancer studies.
BMJ Support Palliat Care
; 2022 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041820
13.
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
JCO Precis Oncol
; 6: e2100484, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36315916
14.
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Expert Opin Investig Drugs
; 30(4): 401-409, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33641556
15.
Applications of single-cell and bulk RNA sequencing in onco-immunology.
Eur J Cancer
; 149: 193-210, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866228
16.
Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials.
JCO Clin Cancer Inform
; 5: 709-718, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34197179
17.
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.
JCO Clin Cancer Inform
; 3: 1-10, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31539266
18.
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
Cell Res
; 29(10): 846-861, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31481761
19.
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Eur J Cancer
; 90: 83-91, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29274619
20.
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Oncotarget
; 9(11): 9741-9750, 2018 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29515767